J&J Seeks Japanese Approval For Simponi With MHLW
This article was originally published in PharmAsia News
Executive Summary
Johnson & Johnson Japanese subsidiary Janssen Pharma submitted a new drug application for antibody rheumatoid arthritis drug golimumab with Japan's Ministry of Health, Labor and Welfare